

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.5%					
BIOTECHNOLOGY - 74.7%					
Amgen, Inc.	20,720	\$ 6,676,191			
Gilead Sciences, Inc.	61,905	5,190,115			
Vertex Pharmaceuticals, Inc.*	9,565	4,448,490			
Regeneron Pharmaceuticals, Inc.*	3,943	4,145,039			
Corteva, Inc.	56,438	3,317,990			
Alnylam Pharmaceuticals, Inc.*	11,100	3,052,833			
Biogen, Inc.*	14,005	2,714,729			
Moderna, Inc.*	40,346	2,696,323			
Illumina, Inc.*	18,489	2,411,151			
United Therapeutics Corp.*	5,787	2,073,771			
Royalty Pharma plc — Class A	69,084	1,954,386			
Insmed, Inc.*	24,177	1,764,921			
Sarepta Therapeutics, Inc.*	13,751	1,717,362			
Incyte Corp.*	25,900	1,711,990			
BioMarin Pharmaceutical, Inc.*	24,243	1,704,041			
Legend Biotech Corp. ADR*	30,903	1,505,903			
BioNTech SE ADR*	11,994	1,424,527			
Argenx SE ADR*	2,618	1,419,165			
REVOLUTION Medicines, Inc.*	30,792	1,396,417			
Exelixis, Inc.*	52,804	1,370,264			
Intra-Cellular Therapies, Inc.*	18,511	1,354,450			
CRISPR Therapeutics AG ^{*1}	28,827	1,354,292			
Halozyne Therapeutics, Inc.*	23,072	1,320,641			
Viking Therapeutics, Inc.*	20,101	1,272,594			
Cytokinetics, Inc.*	23,348	1,232,774			
Blueprint Medicines Corp.*	13,165	1,217,763			
Avidity Biosciences, Inc.*	26,463	1,215,446			
Roivant Sciences Ltd.*	102,527	1,183,162			
Ionis Pharmaceuticals, Inc.*	29,368	1,176,482			
Ultragenyx Pharmaceutical, Inc.*	19,704	1,094,557			
Crinetics Pharmaceuticals, Inc.*	20,024	1,023,226			
Axsome Therapeutics, Inc.*	10,647	956,846			
Bridgebio Pharma, Inc.*	36,536	930,207			
Dyne Therapeutics, Inc.*	25,778	925,946			
TG Therapeutics, Inc.*	39,286	918,900			
Amicus Therapeutics, Inc.*	82,481	880,897			
Iovance Biotherapeutics, Inc.*	88,004	826,358			
PTC Therapeutics, Inc.*	21,857	810,895			
Guardant Health, Inc.*	35,089	804,942			
Nuvalent, Inc. — Class A*	7,820	799,986			
Apellis Pharmaceuticals, Inc.*	27,159	783,266			
Novavax, Inc. ^{*1}	60,657	766,098			
Arrowhead Pharmaceuticals, Inc.*	38,866	752,834			
Intellia Therapeutics, Inc.*	35,674	733,101			
ACADIA Pharmaceuticals, Inc.*	44,830	689,485			
SpringWorks Therapeutics, Inc.*	21,493	688,636			
Recursion Pharmaceuticals, Inc. — Class A ^{*1}	103,389	681,334			
Immunovant, Inc.*	23,790	678,253			
Ardelyx, Inc.*	98,198	676,584			
Dynavax Technologies Corp.*	56,493	629,332			
Beam Therapeutics, Inc.*	23,602	578,249			
Krystal Biotech, Inc.*	3,081	560,834			
Akero Therapeutics, Inc.*	17,826	511,428			
Sage Therapeutics, Inc.*	43,626	\$ 314,980			
Total Biotechnology					<u>83,040,386</u>
PHARMACEUTICALS - 19.7%					
AbbVie, Inc.	49,204	9,716,806			
AstraZeneca plc ADR	38,104	2,968,683			
Vaxcyte, Inc.*	16,335	1,866,600			
Viartis, Inc.	159,683	1,853,920			
Neurocrine Biosciences, Inc.*	14,645	1,687,397			
Alkermes plc*	53,379	1,494,078			
Jazz Pharmaceuticals plc*	12,083	1,346,167			
Madrigal Pharmaceuticals, Inc.*	2,607	553,257			
Ironwood Pharmaceuticals, Inc. — Class A*	89,285	367,854			
Total Pharmaceuticals					<u>21,854,762</u>
HEALTHCARE-PRODUCTS - 4.1%					
Natera, Inc.*	15,628	1,983,975			
Exact Sciences Corp.*	26,518	1,806,406			
Twist Bioscience Corp.*	18,478	834,836			
Total Healthcare-Products					<u>4,625,217</u>
HEALTHCARE-SERVICES - 1.0%					
Medpace Holdings, Inc.*	3,291	1,098,536			
Total Common Stocks (Cost \$55,582,282)					<u>110,618,901</u>
				FACE	
				AMOUNT	
REPURCHASE AGREEMENTS^{††2} - 0.7%					
J.P. Morgan Securities LLC issued 09/30/24 at 4.86% due 10/01/24			\$ 399,392		399,392
BofA Securities, Inc. issued 09/30/24 at 4.85% due 10/01/24			329,879		<u>329,879</u>
Total Repurchase Agreements (Cost \$729,271)					<u>729,271</u>
				SHARES	
SECURITIES LENDING COLLATERAL^{†3} - 2.0%					
Money Market Fund^{***}					
First American Government Obligations Fund - Class X, 4.82% ⁴			2,236,257		<u>2,236,257</u>
Total Securities Lending Collateral (Cost \$2,236,257)					<u>2,236,257</u>
Total Investments - 102.2% (Cost \$58,547,810)					<u>\$ 113,584,429</u>
Other Assets & Liabilities, net - (2.2)%					<u>(2,487,884)</u>
Total Net Assets - 100.0%					<u>\$ 111,096,545</u>

BIOTECHNOLOGY FUND

* Non-income producing security.

*** A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at September 30, 2024.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of September 30, 2024.

ADR — American Depositary Receipt

plc — Public Limited Company